Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian Bot

Showing results (81-90 of 112) with videos related to

Pageof 12
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|March 26, 2008
Antigen kinetics determines immune reactivityPål Johansen, Tazio Storni, Lorna Rettig, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2011
Intra-lymph node prime-boost vaccination against Melan A and tyrosinase for the treatment of metastatic melanoma: results of a phase 1 clinical trialAntoni Ribas, Jeffrey S Weber, Bartosz Chmielowski, et al.
Cancer Immunology Research|February 13, 2026
Targeted Lipid Nanoparticle Delivery of FAP-CAR mRNA Enables Potent In Vivo T-Cell Engineering Against Pancreatic TumorsKhuloud Bajbouj, Zebin Xiao, Leslie Todd, et al.
Blood|June 14, 2018
Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHLJohn Rossi, Patrick Paczkowski, Yueh-Wei Shen, et al.
Nature Reviews. Drug Discovery|September 30, 2025
In vivo chimeric antigen receptor (CAR)-T cell therapyAdrian Bot, Andrew Scharenberg, Kevin Friedman, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 21, 2024
IL7 increases targeted lipid nanoparticle-mediated mRNA expression in T cells in vitro and in vivo by enhancing T cell protein translationCaitlin M Tilsed, Barzan A Sadiq, Tyler E Papp, et al.
Cancer Discovery|December 18, 2020
A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell ImmunotherapyRanjan Upadhyay, Jonathan A Boiarsky, Gvantsa Pantsulaia, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 28, 2017
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive LymphomaFrederick L Locke, Sattva S Neelapu, Nancy L Bartlett, et al.
Blood Advances|October 9, 2020
Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphomaFrederick L Locke, John M Rossi, Sattva S Neelapu, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 14, 2020
A Phase I, Open-label, Dose-escalation, and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With AdGMCA9 (DC-AdGMCAIX) in Patients With Metastatic Renal Cell CarcinomaIzak Faiena, Begoña Comin-Anduix, Beata Berent-Maoz, et al.
Pageof 12

Showing results (81-90 of 112) with videos related to

Sort By:
Pageof 12
Proceedings of the National Academy of Sciences of the United States of America|March 26, 2008
Antigen kinetics determines immune reactivityPål Johansen, Tazio Storni, Lorna Rettig, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2011
Intra-lymph node prime-boost vaccination against Melan A and tyrosinase for the treatment of metastatic melanoma: results of a phase 1 clinical trialAntoni Ribas, Jeffrey S Weber, Bartosz Chmielowski, et al.
Cancer Immunology Research|February 13, 2026
Targeted Lipid Nanoparticle Delivery of FAP-CAR mRNA Enables Potent In Vivo T-Cell Engineering Against Pancreatic TumorsKhuloud Bajbouj, Zebin Xiao, Leslie Todd, et al.
Blood|June 14, 2018
Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHLJohn Rossi, Patrick Paczkowski, Yueh-Wei Shen, et al.
Nature Reviews. Drug Discovery|September 30, 2025
In vivo chimeric antigen receptor (CAR)-T cell therapyAdrian Bot, Andrew Scharenberg, Kevin Friedman, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 21, 2024
IL7 increases targeted lipid nanoparticle-mediated mRNA expression in T cells in vitro and in vivo by enhancing T cell protein translationCaitlin M Tilsed, Barzan A Sadiq, Tyler E Papp, et al.
Cancer Discovery|December 18, 2020
A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell ImmunotherapyRanjan Upadhyay, Jonathan A Boiarsky, Gvantsa Pantsulaia, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 28, 2017
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive LymphomaFrederick L Locke, Sattva S Neelapu, Nancy L Bartlett, et al.
Blood Advances|October 9, 2020
Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphomaFrederick L Locke, John M Rossi, Sattva S Neelapu, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 14, 2020
A Phase I, Open-label, Dose-escalation, and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With AdGMCA9 (DC-AdGMCAIX) in Patients With Metastatic Renal Cell CarcinomaIzak Faiena, Begoña Comin-Anduix, Beata Berent-Maoz, et al.
Pageof 12